13 Jan 2014 07:00
13 January 2014
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Update re: Acquisition of German based CRO
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, is pleased to announce that the consideration of €0.6m payable for the acquisition of the trade and certain business assets and liabilities of CRM Clinical Trials GmbH, a German based CRO (previously announced on 31 October 2103) has been satisfied by the issue of 1,962,583 Venn shares at the current share price of 25.5 pence. Application has been made for 1,962,583 ordinary shares of 1 pence each to be admitted to trading on 14 January 2014.
Enquiries:
Venn Life Sciences Holdings Plc | |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 |
Paul Foulger, Finance Director | Tel: 020 7933 8797 |
Orla McGuinness, Marketing Manager | Tel: +33 (0)1 30 82 67 07 |
Zeus Capital (Nominated Adviser and Broker) | |
Ross Andrews/Andrew Jones (Corporate Finance) | Tel: 0161 831 1512 |
John Goold (Institutional Sales) | Tel: 0207 533 7716 |
Dominic Wilson (institutional Sales) | Tel: 0207 533 7721 |
Walbrook PR Ltd | Tel: 020 7933 8787 or venn@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
Additional Information:
About Venn Life Sciences Limited: www.vennlifesciences.com
Venn Life Sciences is a Clinical Research Organisation ("CRO") providing a suite of clinical trial management services to pharmaceutical, biotechnology and medical device organisations. With operations in France, Ireland, the Netherlands, Russia, the UK, and a branch office in Switzerland, the Venn Group also includes a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe. The Company's near term objective is the expansion of its coverage to other European countries through strategic acquisitions and organic growth, offering clients a full service, multi-centred capability in Phase II-IV trials and across a range of principal disease areas.